Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Docetaxel - Vivesto

Next Previous
Drug Profile

Docetaxel - Vivesto

Alternative Names: Docecal; Docetaxel micellar - Vivesto; Docetaxel-XR-17; XR-17-docetaxel

Latest Information Update: 12 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oasmia Pharmaceutical
  • Developer Swiss Group for Clinical Cancer Research; Vivesto
  • Class Antineoplastics; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Breast cancer; Prostate cancer

Most Recent Events

  • 12 Sep 2025 Discontinued - Phase-I for Prostate cancer (Metastatic disease, First-line therapy, Hormone refractory) in Switzerland (IV) (Vivesto pipeline, September 2025)
  • 12 Sep 2025 Discontinued - Phase-III for Breast cancer (In adults, In the elderly, Second-line therapy or greater) in Latvia (IV) (Vivesto pipeline, September 2025)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Prostate-cancer(First-line therapy, Hormone refractory, Metastatic disease) in Switzerland (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top